Pivalate’s additional data released from positive Phase II imaging trial in brain metastases

Sydney, Australia - November 23, 2022 - Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London has released additional data related to the F-18 Pivalate (RAD 101) Phase 2a imaging trial in patients with brain metastases.

High contrast images (see below) were seen at 60 minutes after radiotracer injection. The images showed the maximum standardised uptake within lesions compared to the mean differed in a statistically significant manner (Mean ± SEM of 1.54 ± 0.11 vs 0.47 ± 0.04 (p < 0.0001).

The calculated Tumour-to-Background ratio ranged from 1.73 to 6.07 (Mean ± SEM of 3.85 ± 0.33) which supports the assertion of high image contrast in patients regardless of the origin of the primary cancer.

The initial data (announced to the ASX 18 October 2022) showed significant tumour uptake that was consistent and independent from the tumour origin, and also indicated that Pivalate can be used to monitor cerebral metastases.

"The new data released shows the additional benefit of PET scan with F-18 Pivalate in detecting the metabolic activity in the brain metastases" said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "This quality image is a promising indication that the tracer can be used to monitor brain metastases, which is yet another positive step for the potential of this technology for Radiopharm."